Targeted drug combo aims to halt advanced prostate cancer in select patients
NCT ID NCT05689021
Summary
This study is testing a combination of two drugs, niraparib/abiraterone and prednisone, in men with advanced prostate cancer that has spread and has stopped responding to standard hormone-blocking treatments. The treatment is specifically for patients whose cancer has a particular genetic change called a SPOP mutation. The main goal is to see if this combination can significantly lower a key cancer marker (PSA) and control the cancer's growth for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.